Immunovia ABIMMVF -61.59%43 Gross Margin % is 62.50% as of Mar. 2026, which is 99% below its 10-year median of 7,604.49. GuruFocus rates IMMVF with a GF Score™ of 43/100 and a GF Value™ of $0.01. The stock has 4 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, Immunovia AB ranks better than 74.74% on this metric.
The historical rank and industry rank for Immunovia AB's Gross Margin % or its related term are showing as below:
IMMVF'
s Gross Margin % Range Over the Past 10 Years
Min: -324.25 Med: 7604.49 Max: 16234.9
Current: 69.64
During the past 13 years, the highestGross Margin % of Immunovia AB was 16234.90%. The lowest was -324.25%. And the median was 7604.49%.
IMMVF's Gross Margin % is ranked better than 74.74% of 194
companies
in the Medical Diagnostics & Research industry
Industry Median: 50.45
vs IMMVF: 69.64
Immunovia AB had a gross margin of 62.50% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Immunovia AB was 0.00% per year.
Immunovia AB (OTCPK:IMMVF) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Immunovia AB had a gross margin of 62.50% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Immunovia AB Gross Margin % Related Terms
Immunovia AB Gross Margin % Historical Data
* Premium members only.
The historical data trend for Immunovia AB's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IMMVF vs TMO, DHR, IDXX: Gross Margin % Comparison
For the Diagnostics & Research subindustry, Immunovia AB's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunovia AB Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Immunovia AB's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Immunovia AB's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Immunovia AB (IMMVF) has a Gross Margin % of 62.50% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Immunovia AB and its competitors. This is 99% below median its historical median of 7,604.49. According to the industry distribution chart, Immunovia AB ranks #49 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 25.3%.
Is Immunovia AB's Gross Margin % too high?
Immunovia AB's current Gross Margin % of 62.50% is 99% below median its 10-year median of 7,604.49. The Medical Diagnostics & Research industry median Gross Margin % is 50.45. Immunovia AB's value of 62.50% is 23.9% above this industry median. Based on the distribution chart, Immunovia AB ranks #49 out of 194 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Immunovia AB has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Immunovia AB's Gross Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Immunovia AB ranks #49 out of 194 companies for Gross Margin %. This puts Immunovia AB in the upper half of its industry. The industry median Gross Margin % is 50.45. Immunovia AB's value of 62.50% is 23.9% above this benchmark. While the company's 10-year median is 7,604.49 vs. the industry median of 50.45, Immunovia AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 50.45, based on 194 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immunovia AB's current Gross Margin % of 62.50% is 23.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Immunovia AB and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 50.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immunovia AB's current Gross Margin % is 62.50%, which is 99% below median its own 10-year median of 7,604.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunovia AB stock overvalued right now?
Immunovia AB (IMMVF) has a current Gross Margin % of 62.50%. The stock's GF Value™ is $0.01, compared to a current price of $0.02 — trading 100% above its estimated fair value. The current Gross Margin % is 62.50%, which is 99% below median its 10-year median of 7,604.49 and 23.9% above the Medical Diagnostics & Research industry median of 50.45. Immunovia AB's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Immunovia AB (IMMVF), the current Gross Margin % is 62.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immunovia AB (IMMVF) Overvalued in 2026?
Based on GuruFocus' analysis, Immunovia AB stock appears to be overvalued.
The current stock price of $0.02 is trading 100% above its estimated GF Value™ of $0.01.
Key valuation signals for IMMVF:
Gross Margin %: 62.50% (99% below median its 10-year median of 7,604.49)
GF Value™: $0.01 vs. price of $0.02 (100% above fair value)
Industry Position: 23.9% above the Medical Diagnostics & Research median (#49 of 194)
No single metric tells the full story. See the IMMVF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immunovia AB is a diagnostic company. The company develops and commercializes diagnostic tools to detect proteins and autoimmune diseases. The company is developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer. Its technology platform IMMray (TM), is based on antibody microarray analysis.
43GF Score
Get the complete analysis for IMMVF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMMVF has been successfully added to your 
